Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Tab-cel® (tabelecleucel) for Epstein-Barr virus-driven post-transplant lymphoproliferative disease
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):